ClinicalTrials.gg

Haemophilus Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 176 studies for Haemophilus Infections across more than 10 countries. 5 are recruiting or about to start. 54 of them are mainly about Haemophilus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
154
Status unknown
8
Terminated
4
Recruiting
3
Active, not recruiting
3
Not yet recruiting
2

Phase

Phase 3
100
Phase 2
31
Phase 4
21
Phase 1
10

Where

United States
23
Philippines
17
China
17
Germany
14
Finland
11
Poland
11

Who develops what

Add Haemophilus Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 4 companies, 1 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare CanSino Biologics, LG Chem and Tanabe Pharma here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugateEarlier only
Evidence
  • NCT02560272 · Beijing Minhai Biotechnology Co., Ltd · Phase 3 · comparator · “Act-HIB®” · registered Sep 2015
  • NCT02139228 · Novartis · Phase 3 · comparator · “Hib-TT” · registered May 2014
  • NCT01337167 · Merck & Co., Inc · Phase 3 · comparator · “ActHIB™” · registered Apr 2011
  • NCT01214889 · Sanofi · Phase 3 · comparator · “TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine” · registered Oct 2010
  • NCT01062477 · Sanofi · Phase 3 · comparator · “DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine” · registered Feb 2010
GlaxoSmithKline50% of its industry studies00 studies
13-valent pneumococcal vaccineEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04535037 · GlaxoSmithKline · Phase 4 · background · “Pneumococcal 13-valent conjugate vaccine” · registered Aug 2020
  • NCT02096263 · GlaxoSmithKline · Phase 3 · background · “Prevnar13” · registered Mar 2014
  • NCT01978093 · GlaxoSmithKline · Phase 3 · background · “Prevnar 13®” · registered Oct 2013
  • NCT01616459 · GlaxoSmithKline · Phase 2 · comparator · “Prevnar 13™” · registered Jun 2012
  • NCT01480258 · MCM Vaccines B.V. · Phase 3 · background · “Prevenar 13™” · registered Nov 2011
Pfizer73% of its industry studies00 studies
Hepatitis B VaccinesEarlier only
Evidence
  • NCT02447432 · GlaxoSmithKline · Phase 3 · background · “DTPw-HBV/Hib” · registered May 2015
  • NCT01061541 · GlaxoSmithKline · Phase 2 · comparator · “Tritanrix™-HepB” · registered Feb 2010
  • NCT00861380 · GlaxoSmithKline · Phase 3 · comparator · “GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)” · registered Mar 2009
  • NCT00839254 · GlaxoSmithKline · Phase 3 · comparator · “GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)” · registered Feb 2009
  • NCT00534833 · Sanofi · Phase 3 · comparator · “Tritanrix-HepB/Hib™” · registered Sep 2007
—00 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 3 Feb 2027 est.Haemophilus influenzae serotype a vaccine candidate · InventVacc Biologicals Inc. · Phase 2 main aimNCT07743008 Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine — primary endpoint: Immediate Adverse Events Following Immunization · 47 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Haemophilus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, 0 (0%) set no upper age limit and 3 (100%) stop at 75 or younger. 3 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (100%) take healthy volunteers.

Recruiting studies that take each age, of 3
AgeWomenMen
100 (0%)0 (0%)
180 (0%)0 (0%)
300 (0%)0 (0%)
400 (0%)0 (0%)
500 (0%)0 (0%)
650 (0%)0 (0%)
750 (0%)0 (0%)
850 (0%)0 (0%)

Across all 176 studies, recruiting or not: 93% stop at 75 or younger and 93% at 65; 94% take children; 0% are for women only and 1% for men only; 94% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Haemophilus Infections studies take

Of 23 phase 3 interventional studies under Haemophilus Infections, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 311 mo5–21 · 23 studies11 mo5–21 · 23 studies—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 176. Browse all 176 → or search them.